Literature DB >> 11909982

Levodopa strengths and weaknesses.

Joseph Jankovic1.   

Abstract

Despite clinical experience with levodopa for more than three decades, the role of this agent in the treatment of Parkinson's disease (PD) has not been well defined. Clearly the most effective antiparkinsonian drug, levodopa, is associated with emergence of motor complications, particularly fluctuations and dyskinesias, as well as other side effects. In addition to these limitations, there is an ongoing debate about the potential neurotoxic effects of levodopa, suggested by some in vitro studies. However, there is no support for levodopa-induced neurotoxicity from in vivo studies. This review discusses possible mechanisms of levodopa-related complications and therapeutic strategies for their prevention and management.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11909982     DOI: 10.1212/wnl.58.suppl_1.s19

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

1.  Isolation and characterization of mesenchymal stem cells derived from bone marrow of patients with Parkinson's disease.

Authors:  Zhiqing Zhang; Xiaofang Wang; Suping Wang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-04-10       Impact factor: 2.416

2.  Design of an interpolyelectrolyte gastroretentive matrix for the site-specific zero-order delivery of levodopa in Parkinson's disease.

Authors:  Ndidi C Ngwuluka; Yahya E Choonara; Girish Modi; Lisa C du Toit; Pradeep Kumar; Valence M K Ndesendo; Viness Pillay
Journal:  AAPS PharmSciTech       Date:  2013-03-15       Impact factor: 3.246

Review 3.  Optimising levodopa therapy for the management of Parkinson's disease.

Authors:  Fabrizio Stocchi
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

4.  Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar).

Authors:  Margherita Torti; Jhessica Alessandroni; Daniele Bravi; Miriam Casali; Paola Grassini; Chiara Fossati; Cristiano Ialongo; Marco Onofrj; Fabiana Giada Radicati; Laura Vacca; Stefano Bonassi; Fabrizio Stocchi
Journal:  Br J Clin Pharmacol       Date:  2019-09-12       Impact factor: 4.335

5.  The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.

Authors:  Fulvio Bracco; Angelo Battaglia; Carlos Chouza; Erik Dupont; Oscar Gershanik; Jose Felix Marti Masso; Jean-Louis Montastruc
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

6.  Mitochondrial abnormalities in the putamen in Parkinson's disease dyskinesia.

Authors:  Alipi V Naydenov; Fair Vassoler; Andrew S Luksik; Joanna Kaczmarska; Christine Konradi
Journal:  Acta Neuropathol       Date:  2010-08-26       Impact factor: 17.088

Review 7.  Glutamate receptors and Parkinson's disease: opportunities for intervention.

Authors:  Michael J Marino; Ornella Valenti; P Jeffrey Conn
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.

Authors:  Jack J Chen; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

9.  Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease.

Authors:  Sebastien Lopez; Nathalie Turle-Lorenzo; Francine Acher; Elvira De Leonibus; Andrea Mele; Marianne Amalric
Journal:  J Neurosci       Date:  2007-06-20       Impact factor: 6.167

Review 10.  Medical management of levodopa-associated motor complications in patients with Parkinson's disease.

Authors:  Joseph Jankovic; Mark Stacy
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.